<DOC>
	<DOCNO>NCT02276274</DOCNO>
	<brief_summary>This randomize , open-label , crossover study determine effect food combination tablet SYR-322 metformin hydrochloride ( hereinafter refer SYR-322-MET tablet ) orally administer fasting condition morning breakfast Japanese healthy adult male subject .</brief_summary>
	<brief_title>Effect Food Pharmacokinetics Single Oral Dose Administration Fixed-Dose Combination SYR-322 Metformin Hydrochloride Healthy Adult Male Subjects</brief_title>
	<detailed_description>The primary objective clinical trial determine effect food pharmacokinetics single oral dose administration SYR-322-MET tablet Japanese healthy adult male subject</detailed_description>
	<mesh_term>Alogliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . In opinion investigator subinvestigator , subject capable understanding comply protocol requirement . 2 . The subject sign date write , informed consent form prior initiation study procedure . 3 . The subject Japanese healthy adult male . 4 . The subject age 20 35 year , inclusive , time informed consent . 5 . The subject body weight 50 kg BMI â‰¥18.5 kg/m2 &lt; 25.0 kg/m2 screening . 1 . The subject receive investigational compound within 16 week ( 112 day ) prior start study drug administration Period 1 . 2 . The subject receive SYR322 metformin hydrochloride previous clinical study therapeutic agent . 3 . The subject immediate family member , study site employee , dependant relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 4 . The subject uncontrolled , clinically significant neurologic , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , urologic , endocrine disease abnormality , may impact ability subject participate potentially confound study result . 5 . The subject know hypersensitivity drug . 6 . The subject positive urine drug result drug abuse ( define illicit drug use ) screening . 7 . The subject history drug abuse history alcohol abuse within 2 year prior screen visit unwilling agree abstain alcohol drug throughout study . 8 . Subject take excluded medication , supplement , food product time period list Excluded Medications Dietary Products table . 9 . Subject evidence current cardiovascular , central nervous system , hepatic , hematopoietic disease , renal dysfunction , metabolic endocrine dysfunction , serious allergy , asthma , hypoxemia , hypertension , seizure , allergic skin rash . There find subject 's medical history , physical examination , safety laboratory test give reasonable suspicion disease would contraindicate take DPP4 inhibitor biguanides , similar drug class , might interfere conduct study . This include , limited , peptic ulcer disease , seizure disorder , cardiac arrhythmia . 10 . The subject current recent [ within 24 week ( 168 day ) prior initiation study treatment Period 1 ] gastrointestinal disease would expect influence absorption drug ( i.e. , history malabsorption , esophageal reflux , peptic ulcer disease , erosive esophagitis , frequent [ per week ] occurrence heartburn , surgical intervention [ e.g. , cholecystectomy ] ) . 11 . The subject history cancer . 12 . The subject positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV ) , human immunodeficiency virus ( HIV ) antibody/antigen , serological reaction syphilis screen . 13 . The subject poor peripheral venous access . 14 . The subject undergone whole blood collection least 200 mL within 4 week ( 28 day ) least 400 mL within 12 week ( 84 day ) prior start study medication administration Period 1 . 15 . The subject undergone whole blood collection least 800 mL total within 52 week ( 364 day ) prior start study medication administration Period 1 . 16 . The subject undergone blood component collection within 2 week ( 14 day ) prior start study medication administration Period 1 . 17 . The subject screen prior start study medication administration Day 1 Period 1 hemoglobin level &lt; 12.5 g/dL . 18 . The subject screen prior start study medication administration Day 1 Period 1 abnormal ( clinically significant ) 12lead ECG . 19 . Subject abnormal screening prior start study medication administration Day 1 Period 1 laboratory value suggest clinically significant underlying disease subject follow lab abnormality : ALT and/or AST &gt; 1.5 upper limit normal . 20 . Subject , opinion investigator , unlikely comply protocol unsuitable reason .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>